Kato, T., Yoshioka, H., Okamoto, I., Yokoyama, A., Hida, T., Seto, T., . . . Yamamoto, N. (2015). Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. Cancer Sci.
Citación estilo ChicagoKato, Terufumi, et al. "Afatinib Versus Cisplatin Plus Pemetrexed in Japanese Patients With Advanced Non-small Cell Lung Cancer Harboring Activating EGFR Mutations: Subgroup Analysis of LUX-Lung 3." Cancer Sci 2015.
Cita MLAKato, Terufumi, et al. "Afatinib Versus Cisplatin Plus Pemetrexed in Japanese Patients With Advanced Non-small Cell Lung Cancer Harboring Activating EGFR Mutations: Subgroup Analysis of LUX-Lung 3." Cancer Sci 2015.